<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970043</url>
  </required_header>
  <id_info>
    <org_study_id>BJ-NSCLC-IIT-Camrelizumab</org_study_id>
    <nct_id>NCT04970043</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment</brief_title>
  <official_title>A Single Arm, Prospective, and Exploratory Clinical Study of Camrelizumab Combined With Pemetrexed and Carboplatin in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutation Who Failed EGFR-TKI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, prospective, single-center, phase II, exploratory study investigating&#xD;
      Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced&#xD;
      non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness&#xD;
      of cell lung cancer patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, eligible subject will be Subjects will have the opportunity to receive the&#xD;
      treatment of Camrelizumab in combination with pemetrexed and carboplatin therapy .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 Year</time_frame>
    <description>From the date Into this study to tumor progression or death for any</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 Year</time_frame>
    <description>it is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 Year</time_frame>
    <description>The time from the beginning of treatment to the death of the subject due to various reasons, calculated by the intended treatment population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>2 Year</time_frame>
    <description>the rate of CR, PR plus SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 Year</time_frame>
    <description>Cr or PR to the first assessment of PD or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Lung Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+ pemetrexed + platinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab+ pemetrexed + platinum</intervention_name>
    <description>Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.&#xD;
Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.&#xD;
Maintenance treatment period:&#xD;
Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.&#xD;
Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years).</description>
    <arm_group_label>Camrelizumab+ pemetrexed + platinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. The age is 18-70 years old;&#xD;
&#xD;
             2. According to the TNM staging of lung cancer in the 8th edition of the International&#xD;
             Association for the study of lung cancer and the Joint Committee on American&#xD;
             Classification of cancer, non squamous non-small cell lung cancer confirmed by&#xD;
             histology or cytology that can not be treated surgically and can not receive radical&#xD;
             concurrent chemoradiotherapy and locally advanced or metastatic (stage Ⅲ B, Ⅲ C or Ⅳ)&#xD;
             non squamous non-small cell lung cancer;&#xD;
&#xD;
             3. EGFR mutation (deletion of exon 19 and L858R mutation of exon 21) was confirmed by&#xD;
             tumor histology, cytology or hematology before EGFR / - TKI treatment;&#xD;
&#xD;
             4. After EGFR-TKI treatment failure (based on RECIST v1.1, disease progression&#xD;
             confirmed by imaging), it meets any of the following requirements:&#xD;
&#xD;
               1. In the past, the first or second generation EGFR-TKI (such as icotinib,&#xD;
                  gefitinib, erlotinib, afatinib or other first or second generation EGFR-TKI&#xD;
                  listed in China) failed, and the T790M mutation of EGFR 20 exon should be&#xD;
                  confirmed by histology;&#xD;
&#xD;
               2. In the past, he received the first or second generation EGFR-TKI (e.g. icotinib,&#xD;
                  gefitinib, erlotinib, afatinib), and the T790M mutation of EGFR 20 exon was&#xD;
                  confirmed by histology or hematology during or after the treatment failure. Then&#xD;
                  he received the third generation EGFR-TKI (e.g. oxitinib or other&#xD;
                  third-generation EGFR-TKI listed in China) and failed;&#xD;
&#xD;
               3. The patients who received the third-generation EGFR-TKI (such as oxitinib or&#xD;
                  other third-generation EGFR-TKI listed in China) at the time of initial diagnosis&#xD;
                  of EGFR mutant NSCLC and progressed without other targeted treatment&#xD;
                  opportunities;&#xD;
&#xD;
             5. No previous systemic anti-tumor therapy (except EGFR-TKI) for advanced non squamous&#xD;
             NSCLC (for those who have received platinum neoadjuvant chemotherapy or adjuvant&#xD;
             chemotherapy, if the disease progression occurred more than 6 months after the end of&#xD;
             the last treatment, they are eligible to participate in this study);&#xD;
&#xD;
             6. The life expectancy is at least 3 months;&#xD;
&#xD;
             7. ECoG score: 0-1;&#xD;
&#xD;
             8. According to recist1.1, the researcher confirmed that there was at least one&#xD;
             measurable lesion;&#xD;
&#xD;
             9. The function of main organs is normal, and the test results must meet the following&#xD;
             requirements:&#xD;
&#xD;
               1. The standard of blood routine examination should be met (no blood transfusion and&#xD;
                  blood products within 14 days, no correction with G-CSF and other hematopoietic&#xD;
                  stimulating factors)&#xD;
&#xD;
                  A. Hemoglobin (HB) ≥ 90 g / L;&#xD;
&#xD;
                  B. Neutrophil count (ANC) ≥ 2 × 109/L；&#xD;
&#xD;
                  C. Platelet count (PLT) ≥ 100 × 109/L；&#xD;
&#xD;
               2. Biochemical tests should meet the following standards:&#xD;
&#xD;
                  A. Total bilirubin (TBIL) &lt; 1.5 upper limit of normal (ULN);&#xD;
&#xD;
                  B. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5uln,&#xD;
                  but &lt; 5uln for patients with liver metastasis;&#xD;
&#xD;
                  C. Serum creatinine (CR) ≤ 1.5 ULN or endogenous creatinine clearance &gt; 60 ml /&#xD;
                  min (Cockcroft Gault formula);&#xD;
&#xD;
                  D. Urine routine test results showed that urinary protein (Upro) &lt; 2 + or 24-hour&#xD;
                  urinary protein &lt; 1g;&#xD;
&#xD;
             10. Women of childbearing age must have taken reliable contraceptive measures or&#xD;
             conducted pregnancy test (serum or urine) within 7 days before enrollment, and the&#xD;
             result is negative, and they are willing to use appropriate contraceptive methods&#xD;
             during the test period and 60 days after the last administration of the test drug. For&#xD;
             men, it is necessary to agree to use appropriate contraceptive methods or surgical&#xD;
             sterilization during the trial period and 120 days after the last administration of&#xD;
             the trial drug;&#xD;
&#xD;
             11. Signed the written informed consent, and expected to have good compliance with the&#xD;
             research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with active brain metastases (for patients with stable symptoms of brain&#xD;
             metastases after treatment, keep stable for at least 4 weeks);&#xD;
&#xD;
             2. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2&#xD;
             drugs or drugs that stimulate or synergistically inhibit T cell receptors (e.g.,&#xD;
             CTLA-4, OX-40, CD137);&#xD;
&#xD;
             3. Have received systemic anti-tumor therapy (including cytotoxic chemotherapy&#xD;
             combined with radiotherapy) for advanced NSCLC other than EGFR-TKI in the past;&#xD;
&#xD;
             4. Immunosuppressive drugs were used within 14 days before the first use of&#xD;
             karelizumab, excluding nasal and inhaled corticosteroids or physiological doses of&#xD;
             systemic steroids (i.e. not more than 10 mg / day prednisolone or other&#xD;
             corticosteroids with the same physiological dose of drugs);&#xD;
&#xD;
             5. Received systemic treatment of Chinese herbal medicine with anti-tumor indications&#xD;
             or immunomodulatory drugs (including thymosin, interferon and interleukin, except for&#xD;
             local use to control pleural effusion) within 2 weeks before the first administration;&#xD;
&#xD;
             6. Received EGFR-TKI within 2 weeks before the first administration;&#xD;
&#xD;
             7. Received palliative radiotherapy within 7 days before the first administration. For&#xD;
             the patients who had received palliative radiotherapy 7 days before the first&#xD;
             administration, all the following conditions must be met before they can be enrolled:&#xD;
             there is no toxic reaction related to radiotherapy, glucocorticoid is not required,&#xD;
             and radiation pneumonia is excluded;&#xD;
&#xD;
             8. Severe cardiovascular diseases: myocardial ischemia or myocardial infarction above&#xD;
             grade II, poorly controlled arrhythmia (including QTc interval ≥ 450 ms for male and ≥&#xD;
             470 MS for female); Grade Ⅲ - Ⅳ cardiac insufficiency (according to NYHA&#xD;
             classification of New York Heart Association, see Annex 3), or left ventricular&#xD;
             ejection fraction (LVEF) &lt; 50% by echocardiography;&#xD;
&#xD;
             9. Currently participating in interventional clinical research treatment, or receiving&#xD;
             other research drugs or research devices within 4 weeks before the first&#xD;
             administration; Not fully recovered from toxicity and / or complications caused by any&#xD;
             intervention before the first administration (i.e., ≤ grade 1 or baseline, excluding&#xD;
             fatigue or hair loss);&#xD;
&#xD;
             10. With uncontrolled pleural effusion, pericardial effusion, or ascites requiring&#xD;
             repeated drainage (drainage once a month or more frequently);&#xD;
&#xD;
             11. Subjects have received or plan to receive solid organ or blood system&#xD;
             transplantation (except corneal transplantation) during the study period;&#xD;
&#xD;
             12. Patients with active autoimmune disease or immunodeficiency, or with the above&#xD;
             history, including but not limited to: autoimmune hepatitis, interstitial pneumonia,&#xD;
             uveitis, rheumatoid arthritis, inflammatory bowel disease, hypophysitis, vasculitis,&#xD;
             nephritis, etc.) were not included. The following exceptions: Patients with a history&#xD;
             of autoimmune hypothyroidism but receiving thyroid hormone replacement therapy were&#xD;
             included in the study. Patients with type 1 diabetes whose blood glucose is controlled&#xD;
             after insulin administration can participate in this study.&#xD;
&#xD;
             13. Subjects who received systemic therapy such as bronchodilators were not satisfied&#xD;
             with asthma control and could not be included (those who had complete remission of&#xD;
             asthma in childhood and did not need any intervention in adulthood could be included).&#xD;
&#xD;
             14. Severe infection occurred within 4 weeks before the first administration (e.g.&#xD;
             need for intravenous drip of antibiotics, antifungal or antiviral drugs), or fever of&#xD;
             unknown origin &gt; 38.5 ° C occurred during the screening period / before the first&#xD;
             administration; Or received major surgical treatment within 3 weeks before the first&#xD;
             medication;&#xD;
&#xD;
             15. Inoculate live attenuated vaccine within 30 days of the first administration or&#xD;
             expected during the study period;&#xD;
&#xD;
        16.16. Human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome&#xD;
        (AIDS), untreated active hepatitis B, hepatitis C virus (hepatitis C antibody positive, and&#xD;
        HCV-RNA higher than the lower limit of analysis method) or combined hepatitis B and&#xD;
        hepatitis C common sense;&#xD;
&#xD;
        Note: the hepatitis B subjects who met the following criteria also met the inclusion&#xD;
        criteria: HBV viral load must be &lt;1000 copy /ml (200 IU/ml) before the first dose, and the&#xD;
        subjects should be treated with anti HBV therapy during the whole chemotherapy course to&#xD;
        avoid virus reactivation. For the subjects with anti HBC (+), HBsAg (-), anti HBS (-) and&#xD;
        HBV viral load (-), preventive anti HBV treatment is not necessary, but close monitoring of&#xD;
        virus reactivation is needed;&#xD;
&#xD;
        17. Patients with a clear history of allergy are known to have allergic reactions to&#xD;
        carrizumab, pemetrexed, carboplatin or cisplatin active ingredients and or any excipients;&#xD;
&#xD;
        18. Those who have a history of psychotropic drug abuse and can not give up or have mental&#xD;
        disorders;&#xD;
&#xD;
        Other conditions that increase the risk associated with participating in the study or the&#xD;
        study drug and, in the judgment of the investigator, may result in patients not suitable&#xD;
        for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lin Lin, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lin Lin, doctor</last_name>
    <phone>13910388770</phone>
    <email>doctor.linlin@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lin Wang, doctor</last_name>
    <phone>139911085229</phone>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>LIN</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>PD-1 Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

